8-K: Palatin Technologies Announces $11.5 Million Public Offering Amidst NYSE American Delisting

Palatin Technologies prices a public offering for $11.5 million while facing delisting from the NYSE American.

Summary

• Palatin Technologies, Inc. announced the pricing of a public offering to raise $11.5 million through the sale of common stock and warrants.
• The offering includes 76,666,667 shares of common stock (or equivalents) and warrants to purchase the same number of shares.
• The combined public offering price is $0.15 per share and accompanying warrants.
• The company may receive an additional $11.5 million if milestone-related Series G warrants are exercised.
• The Series F warrants have an exercise price of $0.30 per share and expire five years from the issuance date.
• The Series G warrants have an exercise price of $0.15 per share and expire in 24 months or upon FDA acceptance of an obesity treatment compound.
• Series H warrants, issued upon exercise of Series G warrants, have an exercise price of $0.225 per share and expire 24 months from issuance.
• The offering is expected to close around May 8, 2025, pending customary conditions.
• The company intends to use the net proceeds for working capital and general corporate purposes, including obesity program development.
• Concurrently, Palatin Technologies received notice of delisting from the NYSE American due to the low selling price of its common stock.
• Trading was suspended on May 7, 2025, and the shares will transition to the OTC Pink Market on May 8, 2025, under the ticker symbol PTNT.
• Palatin intends to appeal the delisting decision.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the delisting from the NYSE American, which overshadows the positive aspect of the public offering. The company's future is uncertain, pending the appeal and the success of its obesity program.

Positives

• The public offering provides Palatin Technologies with $11.5 million in funding.
• Potential for an additional $11.5 million if Series G warrants are exercised.
• Funds are earmarked for working capital and the development of the obesity program.
• The company intends to appeal the delisting decision.

Negatives

• The company received a delisting notice from the NYSE American due to its low stock price.
• Trading of Palatin's common stock on the NYSE American has been suspended.
• The company's stock transitioned to the OTC Pink Market on May 8, 2025.

Risks

• The company faces the risk of not having its appeal of the delisting decision accepted.
• There is no guarantee that the Series G warrants will be exercised, and the company may not receive the additional $11.5 million.
• The company's stock is now trading on the OTC Pink Market, which may reduce liquidity and investor interest.

Future Outlook

The company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes, including for development work on its obesity program and intends to appeal the delisting decision.

Management Comments

• Carl Spana, Ph.D., President and CEO of Palatin Technologies, stated that they are disappointed with the delisting determination but remain committed to advancing their business plan and increasing stockholder value.

Industry Context

The announcement reflects the challenges faced by smaller biopharmaceutical companies in maintaining stock prices and exchange listings, particularly when funding research and development. The company is focused on melanocortin receptor system modulation, a target area for various diseases.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical sector often pursue public offerings to fund clinical trials and research.
• Delisting from major exchanges can negatively impact investor confidence and stock liquidity, potentially leading to lower valuations.
• Companies like Palatin often seek partnerships or collaborations to offset development costs and commercialize products.
• The terms of the warrants, including exercise prices and expiration dates, are typical for similar financing arrangements in the biotech industry.
• The company's focus on melanocortin receptor system modulation aligns with industry trends in targeted therapies.

Stakeholder Impact

• Shareholders face potential dilution from the public offering.
• Shareholders face potential loss of value due to the delisting from the NYSE American.
• Employees may experience uncertainty due to the company's financial situation and delisting.
• Customers and partners may be concerned about the company's long-term viability.

Next Steps

• Palatin intends to appeal the delisting decision with the NYSE American.
• The company will proceed with the closing of the public offering, expected on or about May 8, 2025.
• The company will use the net proceeds from the offering primarily for working capital and general corporate purposes, including for development work on its obesity program.

Key Dates

Keywords

public offering, warrants, delisting, common stock, Palatin Technologies, NYSE American, OTC Pink Market, financing, biopharmaceutical, obesity program